- Conditions
- Diabetic Gastroparesis, Idiopathic Gastroparesis
- Interventions
- TAK-906 Maleate, Placebo
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 67
- States / cities
- Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 153
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- LB-102
- Drug
- Lead sponsor
- LB Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 25
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more
- Conditions
- Stimulant Use Disorder, Substance-related Disorders
- Interventions
- Repetitive transcranial magnetic stimulation (rTMS)
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Parkinson Disease
- Interventions
- 150% of their routine home dopaminergic medications dose right in the clinic, Evaluation of mathematical models
- Drug · Device
- Lead sponsor
- Stardots AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Manchester, New Hampshire
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- High-dose furosemide, Low-dose furosemide, Low-dose furosemide combined with low-dose dopamine
- Drug
- Lead sponsor
- Larissa University Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Cleveland, Ohio
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Orange, California + 6 more
- Conditions
- Parkinson Disease
- Interventions
- N-0923
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Albinism, Oculocutaneous Albinism
- Interventions
- Levodopa/carbidopa
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Parkinson's Disease
- Interventions
- Apomorphine
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Heart Failure, Diastolic
- Interventions
- Furosemide, Dopamine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- Droxidopa capsules, Placebo capsules
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 168
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
- Conditions
- Migraine Headache
- Interventions
- Propofol, Standard Treatment
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Restless Legs Syndrome, Augmentation
- Interventions
- Ecopipam, Placebo
- Drug
- Lead sponsor
- William Ondo, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Parkinson Disease, Parkinsonian Syndrome
- Interventions
- levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
- Drug · Procedure
- Lead sponsor
- Institute for Neurodegenerative Disorders
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 13
- States / cities
- Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic
- Interventions
- Amantadine, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
- Conditions
- Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure
- Interventions
- Dopamine administration, Norepinephrine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- Up to 28 Days
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Lesch-Nyhan Disease
- Interventions
- Ecopipam
- Drug
- Lead sponsor
- Psyadon Pharma
- Industry
- Eligibility
- 6 Years to 65 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- San Diego, California • Atlanta, Georgia
- Conditions
- Early Course Schizophrenia Spectrum Disorder
- Interventions
- CVL-562 (PF-06412562) 1 mg, CVL-562 (PF-06412562) 4 mg, CVL-562 (PF-06412562) 15 mg, CVL-562 (PF-06412562) 25 mg, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York • Stony Brook, New York + 1 more
- Conditions
- Cocaine Dependence, Opioid Dependence
- Interventions
- Disulfiram, Methadone, CBT, Lactose
- Drug · Behavioral · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Parkinson's Disease
- Interventions
- VY-AADC02, Sham (Placebo) Surgery
- Biological · Other
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Irvine, California • Sacramento, California • San Francisco, California + 8 more
- Conditions
- Healthy
- Interventions
- OROS methylphenidate hydrochloride, methylphenidate hydrochloride
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Safinimide 50-100 mg/day, Matching Placebo
- Drug
- Lead sponsor
- Newron Pharmaceuticals SPA
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
- Conditions
- Infertility
- Interventions
- Follitropin delta, Placebo
- Drug · Other
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 34 Years · Female only
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 23
- States / cities
- Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more